 |
BioWorld-International-2009-04-22
Evotec Options Narrow on Smoking Trial Miss
SpePharm Seeking €35M from BioAlliance Pharma
No Abstract
BioWorld International Correspondent
PARIS - SpePharm Holding BV plans to file a claim against BioAlliance Pharma SA for financial damages and losses of at least €35 million (US$45.3 million).
Evotec Options Narrow on Smoking Trial Miss
Evotec AG's near-term partnering options narrowed on news that its smoking cessation drug EVT 302 failed to demonstrate efficacy in a Phase II proof-of-concept trial involving 414 smokers. (BioWorld International)